Press Releases

CURE debuts “CUREinside” quality mark on the packaging of ReLeaf Europe’s sublingual tinctures and new topical cream product lines  Oxnard, Calif. February 5, 2020 – CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, announced today that it has signed an exclusive licensing agreement with ReLeaf Europe, one of Europe’s leading pharmaceutical groups […]

CURE CEO to discuss company’s expanded technology platform and pharmaceutical pipeline LOS ANGELES, Dec. 05, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced that it will be presenting at the 12th Annual LD Micro Main Event on Wednesday, December 11 at 9:45 AM PST/ 12:45 PM ET at the […]

Industry veteran brings 40 years of experience to support CURE’s rapid growth OXNARD, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced that it has named John K. Bell, FCA, FCPA, ICD.D to its board of directors. Bell brings more than 40 years of experience to […]

OXNARD, Calif., November 14, 2019 – CURE Pharmaceutical (OTC: CURR) (“CURE”), an innovative drug delivery and development company, today announced that it purchased a $200,000 convertible promissory note issued by Coeptis Pharmaceuticals, Inc., a biopharmaceutical company engaged in the acquisition, development and commercialization of branded 505(b)(2) pharmaceutical products. This note represents an initial step toward […]

Alternative dosage demand drives company’s manufacturing expansion OXNARD, Calif., Oct. 09, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, announces the expansion of its oral drug delivery product line creating CUREform™ which includes CUREfilm®, one of the most advanced oral thin films on the market today. The new line adds […]

Biopharma star brings extensive translational research experience as company advances its clinical indications Oxnard, Calif. – October 1, 2019 – CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, has appointed Dr. Vered Gigi as its Chief Scientific Officer. In this role, Dr. Gigi will oversee all CURE’s research and development. Dr. Gigi […]

OXNARD, Calif. – August 21, 2019 – CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced it has signed a deal with Oklahoma-based hemp grower Fytiko Farms. The deal gives CURE direct, guaranteed access to high-quality plant material for exclusive use in its proprietary oral thin film (OTF) drug delivery system, […]

Oxnard, Calif. – August 7, 2019 – CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced the addition of two directors to its Board, Dr. Lauren Chung, Ph.D. and Mrs. Anya Goldin. Dr. Chung has experience in healthcare investments and academic accomplishments in scientific fields and Goldin brings expertise in both […]

OXNARD, Calif. – July 16, 2019 – CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, today announced the allowance of U.S. Application No. 15/666,057, which covers edible thin films with natural active ingredients located in both a powder coating and the film matrix for a bi-phasic release profile. “With an increased consumer demand […]

OXNARD, Calif. – June 19, 2019 – CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced it is collaborating with Canopy Growth Corporation (TSX: WEED) (NYSE: CGC), (“Canopy”) to develop a new low-dose cannabidiol (CBD) oral thin film (OTF) using CURE’s patented CUREfilm™ technology for global distribution. This CUREfilm license gives […]